A Study of Intismeran Autogene (V940) Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)

NCT06077760 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

868

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer

Interventions

BIOLOGICAL: Intismeran autogene
BIOLOGICAL: Pembrolizumab
OTHER: Placebo

Sponsor

Merck Sharp & Dohme LLC

Collaborators

ModernaTX, Inc.